Naturally occurring mutant forms of p53 are deficient for specific DNA binding. However, their specific DNA binding can be reactivated. The search for small molecules that reactivate latent p53 is considered to be a cornerstone in cancer therapy. The authors describe a new homogeneous fluorescent assay approach for the characterization of binding affinities of human wild-type latent and activated p53 using DNA*spec(26), with and without the addition of the antibody PAb421, respectively, and fluorescence correlation spectroscopy (FCS)/2-dimensional fluorescence-intensity distribution analysis anisotropy as the detection methods. FCS was compared with 2D-FIDA anisotropy, and a very good correlation of the results with both readouts was observed (K D s for nonspecific DNA binding of 24.4 ± 3.5 nM with 2D-FIDA anisotropy and of 29.5 ± 5.5 nM with FCS). The presence of poly(dI-dC) led to a 10-fold increase of binding affinity (K D of 3.3 ± 0.5 nM in the presence of PAb421). 2D-FIDA anisotropy was demonstrated to be the most accurate readout; hence, this detection technology was selected for a 25,000 compound member high-throughput screening (HTS) campaign. The hits obtained were qualified using a novel data evaluation algorithm that identifies false positives and moreover assesses the validity of true hits in the presence of the deteriorating artifact. This process step is of utmost importance for decreasing the attrition in fluorescence-based HTS. (Journal of Biomolecular Screening 2006:341-350) 
T HE TUMOR-SUPPRESSOR PROTEIN p53 is of great importance for cell-cycle control, DNA repair and recombination, apoptosis, and centrosome duplication. [1] [2] [3] The specific DNA binding activity of p53 is crucial for its tumor suppression function. Naturally occurring oncogenic mutant forms of p53, which are found in about 50% of all human cancers, are deficient for specific DNA binding. For the development of new therapeutic strategies, 1 focus is to enhance or reconstitute the p53-dependent activities of the so-called allosteric mutants of p53. 4, 5 These p53 mutants have an intrinsic capacity to bind to DNA, but mutations prevent kinase activation. Short peptides derived from the p53 C-terminus [6] [7] [8] [9] and antibodies binding to the kinase phosphorylation site 10, 11 reactivate these mutant p53 proteins and trigger a p53-dependent biologic response. Hence, such molecules, further developed into small-molecule activators, may provide a basis for the design of p53-reactivating anticancer drugs. 12, 13 The same functions that enable human wild-type p53 to eliminate cancer cells can conversely be suppressed so that normal tissues are protected from the destructive effect of genotoxic stress. Chemotherapy and radiation therapy often have severe side effects that limit their efficiency. Thus, inhibitors of p53 may be useful drugs for reducing the side effects of cancer therapy and other types of stress associated with p53 induction. Data showing that p53-dependent apoptosis are observed in sensitive tissues shortly after gamma irradiation confirm this assumption, as well as the fact that p53-deficient mice survive higher doses of gamma radiation than wild-type animals do. 14, 15 Moreover, a p53 inhibitor protecting mice from the lethal genotoxic stress associated with anticancer treatment was identified using a reporter gene assay. 16 To identify effectively either activators or inhibitors of specific p53-DNA binding, one needs to address a generic assay principle aimed at analysis of latent or activated p53 protein, respectively. The routine production of latent p53 is a challenge that needs a careful preparative protein separation and purification protocol.
Common standard assay methods detecting the interaction between p53 and DNA are electrophoretic mobility shift assays (EMSA) and surface plasmon resonance. The major disadvantages of both procedures are that only apparent binding constants can be determined because these methods are not solution based and that neither of these methods can be used in high-throughput screening (HTS) . In contrast to that, single-molecule spectroscopic detection methods like fluorescence correlation spectroscopy (FCS) and fluorescence-intensity distribution analysis (FIDA, 2D-FIDA anisotropy) allow the investigation of kinetic and thermodynamic binding parameters in solution. [17] [18] [19] [20] Because of their fluorescent, homogeneous, and single-molecule detection nature, these assay methods are well suited to miniaturized HTS, a key technology in state-of-the-art drug discovery.
We describe here a new, efficient production protocol of both human wild-type latent and activated p53 and the development of a miniaturized, homogeneous assay format based on the 2D-FIDA anisotropy readout. The characterization of binding affinities of human wild-type latent and activated p53 to fluorescently labeled DNA is outlined. The application of the assay to a pilot HTS campaign to identify activators of human wild-type p53 in a model compound library is described, and the strength of the readout to discriminate false positive autofluorescent compounds from truly activating compounds is discussed.
MATERIALS AND METHODS

Cloning and expression of p53
The coding region of the human p53 gene was amplified from a human T-cell cDNA source and cloned into the pZero-Blunt PCR cloning vector (InVitrogen, Karlsruhe, Germany). Correct clones were subsequently verified by sequence analysis before being subcloned into the FastBac baculovirus expression vector (InVitrogen). High titer virus stocks were generated in Sf9 cells grown in Insect Express serum free medium (Cambrex Bio Science, Apen, Germany) by standard methodologies.
Extraction of p53 from infected Sf9 cells
Log phase Sf9 cells (1 × 10 6 cells/mL) grown in spinner culture bottles were infected at a multiplicity of infection (MOI) of 5 with human wild-type p53 baculovirus and incubated for 60 h at 27°C in volumes of 400 to 500 mL in Insect Express medium (Cambrex). The cells were harvested by centrifugation for 5 min at 500 g and 4°C. All the following procedures were performed on ice and in the cold room. The cells (~1 × 10 8 ) were suspended gently in 40 mL ice-cold phosphate-buffered saline (PBS) and washed 4 times with 40 mL PBS for 5 min at 500 g and 4°C. Finally, the cell pellet was resuspended in 10 mL 10 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) pH 7.4, 1.5 mM magnesium chloride (MgCl 2 ), and 5 mM potassium chloride (KCl, buffer A containing protease inhibitors-EDTA, Complete, Roche). The cells were then incubated on ice for 60 min before the addition of dithiothreitol (DTT) to 5 mM and subsequently homogenized in a glass DOUNCE homogenizer with 30 strokes and further incubated on ice for 45 min. The suspension was then centrifuged for 10 min at 5000 g at 4°C, resulting in a pellet and a supernatant. The supernatant (fraction A) was removed, and the pellet was resuspended gently in 10 mL, 10 mM HEPES pH 9.0, 1.5 mM MglC 2 , 5 mM KCl and protease inhibitors, and 5 mM DTT (buffer B) and incubated on ice for 45 min. The suspension was then centrifuged for 10 min at 5000g at 4°C, resulting in a pellet and a supernatant (fraction B1). The resulting pellet was washed with buffer B and centrifuged as above, resulting in a pellet and supernatant (fraction B2). This procedure was repeated with buffers C (10 mL, 10 mM HEPES pH 9.0, 1.5 mM MgCl 2 , 200 mM KCl and protease inhibitors, and 5 mM DTT) and D (10 mL, 10 mM HEPES pH 9.0, 1.5 mM MgCl 2 , 500 mM KCl and protease inhibitors, and 5 mM DTT), resulting in supernatant fractions C and D. All supernatants were clarified by centrifugation at 100,000g for 30 min and 4°C. The resulting supernatants were assayed for protein content by the method of Bradford (BioRad, Munich, Germany) and subsequently aliquoted and stored at -80°C.
Purification of human wild-type p53 by affinity purification
For this methodology, Sf9 cells were infected and harvested as above; however, the cells were then lysed in 10 mL 50 mM tris-HCl pH 7.5, 5 mM EDTA, 1% NP-40, 5 mM DTT, 0.1 M sodium chloride (NaCl, buffer E) and protease inhibitors and then incubated on ice for 20 min, followed by centrifugation at 10,000g for 20 min at 4°C. The supernatant was removed and either stored at -80°C or immediately diluted 3-fold with 10% glycerol, 25 mM HEPES pH 7.5, 0.1% Triton X-100, 5 mM DTT (buffer F) and applied to a Heparin Hi-Trap column (Amersham Biosciences, Freiburg, Germany) at a flow rate of 2.5 mL/min using an ÄKTA explorer (Amersham Biosciences). After extensive washing with the same buffer, the bound proteins were eluted with either a linear gradient of 0 to 1 M KCl or a step elution profile of 0.2, 0.6, and 1 M KCl in buffer F. Collected fractions were assayed for protein content by the method of Bradford and subsequently desalted with a Hi-Trap desalting column (Amersham Biosciences) against buffer F. Pools were assayed for protein content by the method of Bradford and subsequently aliquoted and stored at -80°C.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis of human wild-type p53
Protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and either stained with COOMASSIE blue or transferred to polyvinylidene difluoride (PVDF) membranes by standard methodologies. The blots were probed with the p53-specific monoclonal antibodies DO-1 and Bp53 (Santa Cruz Biotechnology, Santa Cruz, CA) and developed with HRP conjugated 2nd antibodies and the ECL detection kit (Amersham Biosciences).
DNA binding assay
The double-stranded (ds) oligodeoxyribonucleotide (ODN) applied as DNA substrate was named DNA*spec (26) and had the following sequence from 5′ to 3′ end:
The complementary, unlabeled strand is not shown. The ODN has blunt ends. The recognition sequence of p53 is underlined in the strand shown. The abbreviation TAMRA stands for the fluorophor 5-carboxytetramethylrhodamine and is indicated by the asterisk (*) in the name of the ODN. The ODN given above was hybridized to its complementary strand in 200 mM HEPES, 25 mM DTT, 250 mM KCl, 0.05% (weight per volume) Tween-20 to 95°C for 2 min and slowly cooled to room temperature over 2 h. Subsequently, the concentration of fluorescently labeled dsDNA was determined by FCS. The sequence of DNA*spec (26) 21 of the p53-DNA interaction. The ODN strands were purchased from NAPS (Göttingen, Germany).
A proprietary confocal fluorescence reader (EVOTEC Technologies, Hamburg, Germany) was used for FCS and rotational diffusion (2D-FIDA anisotropy) studies. An attenuated (to about 800 µW) beam from an He-Ne laser, wavelength 543 nm, was focused to a spot of approximately 0.25 µm radius and resulted in a diffusion time of approximately 60 µs and a molecular polarization of 35 mP for TAMRA. The excitation intensity was generally kept lower than or equal to a level characterized by approximately 15% amplitude of the triplet term of the autocorrelation function. Fluorescence emission was detected through a pinhole on the focal plane of the microscope using an avalanche photodiode detector SPCM-AQ 131 (EG&G) at 590 nm (bandwidth, 35 nm).
For the binding experiments, p53 was incubated with DNA*spec(26) for 15 min at 20°C. In case of activation of the sequence-specific DNA binding of p53 by the antibody PAb421, the protein was preincubated with PAb421 (Calbiochem-Novabiochem, Beeston/Nottingham, United Kingdom) at 20°C before the addition of the DNA. All experiments were performed in binding buffer [15 µL; PBS, pH 6.9, 0.05% Tween-20, 1 ng/µL poly(dI-dC)]. The concentrations of p53, DNA, and antibody applied in the experiments, as well as the observed diffusion times or relative molecular polarizations of the different complexes formed in solution, are given in the text or in the figures. Samples were transferred to a Labtec chamber (NUNC, Naperville, Illinois) for measurements in an overall assay volume of 15 µL and to NanoCarriers™ 2080 (Evotec Technologies Hamburg, Germany) for measurements in an overall assay volume of 1 µL.
Data evaluation
Proprietary software (Evotec Technologies) was used for quantification of translational and rotational diffusion times, molecular brightness, polarization values, and binding degrees. Fluorescence intensity distribution analysis 22 has been recently developed as a complement to FCS. 23 The 2-dimensional FIDA (2D-FIDA), 24 if used with a polarization cube (2D-FIDA anisotropy), is a tool that is able to distinguish fluorescent species with different specific polarization ratios. A novel algorithm, recently developed at Evotec, to evaluate such 2D-FIDA anisotropy data takes advantage of the discrimination of molecular species with different fluorescent properties (e.g., molecular brightness) detected by the confocal FCS + plus technology.
Autofluorescent compounds and the fluorescently labeled ligand DNA*spec (26) are examples for molecular species with different fluorescent properties. Despite the significant contribution of autofluorescent compounds to the total fluorescence intensity observed in a sample, often the molecular brightness of such autofluorescent compounds is much lower than the molecular brightness of the fluorescently labeled ligand. Consistent with this finding, the number of autofluorescent particles is much higher than the number of the fluorescently labeled molecules. This allows one to separate signals caused by autofluorescent species from the signal derived by the fluorescently labeled ligand. The concentration-dependent binding data were fitted to a hyperbolic binding curve using the program Microcal Origin 6.0 (Microcal Software, Northampton, Massachusetts).
RESULTS AND DISCUSSION
p53 expression and purification
The methods employed for the purification of human p53 are almost as varied as the wide variety of sources from which it has been isolated. Thus, for the studies intended and presented in this article, a robust and reproducible expression system combined with a fast and efficient purification strategy was of utmost importance. Furthermore, considering the amounts of material required for uHTS screening, the methodology chosen should also be amenable to laboratory scale-up procedures. For the reasons outlined above, the baculovirus Sf9 expression system was chosen.
Initial experiments using suspension cultures infected with an MOI of 5 for 48 h gave reproducible results with respect to the kinetics of p53 expression as detected by Western blotting using 2 mouse monoclonal antibodies DO-1 and Bp53 that recognize epitopes from both the amino and carboxyl termini of the mature wild-type protein. The aim of the study was to isolate enough activated and latent human wild-type p53 of sufficient purity to develop assays to detect and quantify these different forms of the molecule and to perform subsequently HTS screens using the EVOscreen™ platform (Evotec Technologies). The initial purification protocol based on salt extraction and fractionation from infected Sf9 nuclei according to the method of Kim et al. 25 gave very reproducible results with respect to protein recovery and purity with the majority of the p53 protein being found in the 200 mM KCl fraction with purities approaching 80% (Fig. 1A) . DNA binding analysis, however, demonstrated that although a small proportion of the p53 was latent in nature, the large proportion of the protein was of an activated species. Cross-linking analysis using glutaraldehyde and subsequent SDS-PAGE and Western blot analysis demonstrated that more than 90% of the p53 was tetrameric of nature and only small proportions were either of monomeric or dimeric nature ( Fig. 1B) . Various attempts to increase the proportions of latent p53 using this methodology by varying the MOI used, the duration of infection, and the addition of kinase inhibitors (to modulate the phosphorylation of the p53) to the cells during infection gave no reproducible results. Thus, although this methodology was very efficient and simple for the production of predominantly activated p53, it was not the method of choice for the isolation of predominantly latent p53, in contradiction to previously published results. Thus, a 2nd strategy based on the affinity chromatography of Sf9 cell lysates using heparin was developed using modifications of a previously published methodology. 26 Elution of the bound crude cell lysates with a 2step elution profile of 20 (200 mM) and 60% (600 mM) KCl, respectively, resulted in the release of a minor broad peak and a major sharp peak of p53-containing material (as detected by Western blot analysis, Fig. 1C ) and increased both the yield and the purity of the latent and activated p53 species, as shown in SDS-PAGE and DNA-binding tests (see Inhibition of DNA Binding and Activation of DNA Binding). This procedure was very reproducible, and the yields of latent p53 were approximately 20% of those of the active p53, as shown by functional analysis. This procedure was then used for the scale-up production of enough latent p53 material for assay development and a small HTS screen from a total of 8 L of infected Sf9 cells.
Principle of p53-DNA-binding assay
Recently Wölcke et al. described how the confocal detection method, FCS, could be applied to quantitatively measure the binding of DNA to p53 in solution 21 and characterized the different DNA-binding modes of latent and activated p53. Fluorescence correlation spectroscopy is based on differences in molecular translational diffusion of molecules of different molecular weight. Here, this assay principle was transferred to the confocal detection method of molecular polarization, based on 2D-FIDA anisotropy, and was miniaturized to a total assay volume of 1 µL. This readout also follows the change in molecular mass associated with the binding event. The difference of the rotational diffusion times of unbound fluorescently labeled DNA and the DNA bound to p53 tetramers is quantified. In contrast to FCS, 2D-FIDA anisotropy attained better Z′ factors 27 than did FCS for this assay class under the same measurement conditions and is, therefore, more suitable for HTS. One advantage of all confocal detection methods is their insensitivity to miniaturization. Thus, the HTS assay could be miniaturized to a total assay volume of 1 µL per well without loss of signal to noise and without changing the binding properties.
A very important advantage of 2D-FIDA anisotropy is the ability to identify false positive library compounds, originating from inherent autofluorescent properties of the chemical entities. As confocal detection methods allow one to analyze individual molecules, different molecular species can be discriminated on the basis of their fluorescence properties. Therefore, the contribution of autofluorescent library compounds, which disturbs other fluorescence-based assay formats, can be eliminated, thus reducing the number of false-positive hits without overlooking true activators or inhibitors of p53.
Inhibition of DNA binding
The purified p53 fraction characterized to be fully active for DNA binding (see p53 Expression and Purification) was tested in the homogenous assay for its state of DNA binding activity using DNA*spec (26) , with and without addition of the antibody PAb421, respectively (Fig. 2) , applying FCS as the detection method. Diffusion times of τ D = 235 ± 30 µs for the unbound DNA*spec (26) , of τ D = 802 ± 45 µs for the binary complex of p53 and DNA*spec (26) , and of τ D = 1050 ± 50 µs for the ternary complex of PAb421, p53, and DNA*spec(26) were determined. In addition, the percentages of all 3 molecule species were quantified. The binding affinities of p53 to DNA*spec (26) in the presence (K D = 4.1 ± 1.5 nM) and in the absence (K D = 3.6 ± 1.3 nM) of the antibody were in good correspondence and correlated very well with literature data. 20 Thus, the p53 was indeed already fully activated by cellular events, and no further addition of PAb421 was necessary in this assay to shift the equilibrium between latent and activated p53 to the active conformation to ensure full DNA-binding activity. The activated p53 can directly be used to identify inhibitors of specific p53-DNA interaction in an HTS campaign. A concentration of 10 nM activated p53 and of 2 nM DNA*spec (26) are recommended to achieve a sensitive and robust dynamic range with Z′ factors above 0.5. As a positive control, 50 to 100 nM unlabeled DNA*spec(26) could be used.
Activation of DNA binding
To compare FCS and 2D-FIDA anisotropy, both were applied as detection methods for the titration of human wild-type latent p53 with DNA*spec (26) in the absence of activating molecules. A very good correlation of the results with both readouts was observed, as shown by the K D s for nonspecific DNA binding of 24.4 ± 3.5 nM with 2D-FIDA anisotropy (Fig. 3A) and of 29.5 ± 5.5 nM with FCS ( Fig. 3B) . These results also confirm the respective literature data very well. 24 As the statistical parameters, that is Z′, were found to be significantly improved for the individual measurements, the 2D-FIDA anisotropy readout was chosen for all subsequent measurements and for the application in the HTS campaign. It was planned to perform an HTS campaign with a miniaturized assay format. Therefore, the titration described above was repeated at a total assay volume of 1µL in a NanoCarrier™ 2080. The resulting K D of 28.7 ± 3.5 nM and the size of the standard deviations of the measurements at different p53 concentrations ( Fig. 3C) underline the insensitivity of confocal readouts for miniaturization. Molecular fluorescence properties (e.g., translational [FCS] and rotational [2D-FIDA anisotropy] diffusion of individual molecules) are inherently insensitive to miniaturization because the detection volume of ~1 fL is effectively decoupled from the assay volume. 28 To confirm that the homogeneous assay format described enables the detection of molecules activating the specific p53-DNA interaction, the affinity of latent human wild-type p53 for its DNA recognition sequence was measured both in the presence and in the absence of the antibody PAb421. This antibody stabilizes and activates the DNA-binding conformation, supposedly through disruption of the interaction between the Cterminal domain and its intramolecular binding site within p53. 7 The effect of the activator by measuring the molecular polarization of DNA*spec (26) in the presence of poly(dI-dC) (1 ng/µL) at various p53 concentrations could be clearly demonstrated by a 10-fold increase of binding affinity to a K D of 3.3 ± 0.5 nM in the presence of PAb421 (Fig. 3D) . The same titration was performed in the absence of PAb421, showing that the nonspecific DNA binding of latent p53 is effectively masked by the binding of the unlabeled poly(dI-dC). These results are in good correspondence to the affinity measurements of DNA*spec (26) to fully active p53 (see Inhibition of DNA Binding) and to literature data. 24 The addition of unlabeled, nonspecific DNA enables the use of higher concentrations of human wild-type latent p53 in the HTS campaign described below.
Screening results
The miniaturized p53-activation assay was applied to a pilot HTS run on the EVOscreen™ platform 29 (Evotec Technologies) to identify false-positive activators of latent human wild-type p53 in a compound library containing chemical entities with autofluorescent properties and to characterize them by making use of the power of 2D-FIDA anisotropy (see Hit Validation). The assay format can easily be applied for the identification of compounds reconstituting the DNA-binding properties of the allosteric class 30 of mutants of p53.
The screen was performed in a total assay volume of 1 µL on NanoCarriers™ 2080. Although the difference in binding affinities for DNA*spec(26) between latent and activated p53 was only a factor of 10, a relatively high p53 concentration of 30 nM could be used in the HTS run because nonspecific poly(dI-dC) was added, masking the nonspecific DNA binding of p53 in the latent state.
Altogether, 31,198 data points were generated, consisting of 23,446 compound and 7752 control data. The histogram of all data (Fig. 4) shows a clear separation of the activated, specific DNA binding (positive controls) from the nonbinding (negative controls) situation. Consequently, the threshold based on 4763 socalled negative compound controls was found at 32% activation, based on the mean activation of the controls plus 3 standard deviations. The negative compound controls were chosen as negative control data for the statistical analysis because they were symmetrically distributed over the NanoCarrier™ 2080 and, therefore, represent the assay performance on the plate very well. These controls originate from reformatting 384-well compound plates containing empty columns 23 and 24 onto the NanoCarrier™ 2080. In contrast to the negative compound controls, the so-called negative controls were located on discrete control lines only.
The quality of the screen was evaluated on the basis of the Z factor. This factor reflects both the signal dynamic range and the data variation associated with the signal measurements, and therefore was suitable for assay quality assessment. 27 A mean Z′ factor of 0.61 calculated from positive and negative controls and a mean Z factor of 0.46 calculated from compounds and positive controls were determined for the screening run, underlining the high performance of the screen.
First, 9950 compounds were screened at a compound concentration of 28.5 µM. A hit rate of only 0.1% was determined after online evaluation of the HTS statistics. Therefore, the compound concentration was enhanced to 57µM for the remaining compounds of the library during the ongoing HTS campaign to enable the identification of a substantial number of hits for subsequent validation of the novel data evaluation algorithm. Then, 13,496 compound data were generated at 57µM, including 2856 compounds that were screened 3 times for pilot hit confirmation. Seventy-six primary hits were detected among the compounds screened 3 times. Forty-two (55%) of them were detected as hits in more than 50% of the measurements and are thus classified as confirmed hits and can be further characterized in subsequent hit validation steps. 
Hit validation
One challenge in the drug discovery process is to minimize the propagation of false-positive compounds. Because screening has now been brought close to perfection, the effective validation of the wealth of hits identified becomes more and more important. It is a crucial step to shorten the time and the costs moving forward from target to lead.
As demonstrated above, the combination of a novel p53 purification protocol, optimal binding conditions, and the proprietary Evotec technology 2D-FIDA anisotropy allows the performance of ultra-HTS for inhibitors or even activators of p53. Fluorescence polarization/anisotropy is one of the mostly used detection methods in screening. However, the presence of small autofluorescent compounds can affect the overall polarization of a sample by their own polarization signal leading to false-positive hits. Thus, the early identification of such false positives is very important.
A novel data evaluation algorithm recently developed at Evotec allows not only the identification of false positives but also the assessment of the inhibition or activation power of true hits in the presence of autofluorescence. This method is based on the different fluorescent properties (e.g., molecular brightness) of autofluorescent compounds and the fluorescently labeled DNA ligand DNA*spec(26) used in our DNA-binding assay (for more details, see Materials and Methods). Both fluorescent species can be distinguished on the molecular level and can be mathematically separated during data evaluation. This new method was applied in our pilot screen for activators of p53.
Compounds that led to an overall increase in the polarization signal, suggesting activation of p53, were analyzed in more detail. One example is shown in Figure 5 . Increasing concentrations of the compound EVO-A4 resulted in increasing polarization values, indicating p53 activation. However, an increase in the count rate of exactly the same samples was also seen, suggesting that the compound itself is autofluorescent. It is interesting that after applying the autofluorescence correction algorithm, the dose-dependent activation was not observed anymore. Thus, such compounds can be classified as false positives.
To demonstrate that the activity of compounds can be determined even in the presence of autofluorescence, a simulation was performed (Fig. 6) . Wild-type-latent p53 was about 80% activated by the addition of 20 nM PAb421 (sample S0). In parallel, 2 corresponding samples were set up. The 1st one contained the autofluorescent compound described above (EVO-A4), which increases the polarization (sample S1). The 2nd one contained Rhodamine Green™ (Molecular Probes, Leiden, the Netherlands), which was suggested to lower the polarization of the sample because of its low intrinsic polarization signal (sample S2). Indeed, the overall polarization signal, and hence the apparent activation of wild-type-latent p53, was affected by these compounds as assumed (Fig. 6A) FIG. 5. Evaluation of the dose-dependent change in polarization. The compound EVO-A4 was analyzed in the p53 activation assay in 12 different concentrations (as indicated on the x-axis). The analysis was performed on a NanoCarrier™ (EVOTEC Technologies, Hamburg, Germany) plate. The assay volume was 1.1 µL containing 150 nM wild-type-latent p53 and 6 nM DNA*spec (26) . The polarization (y-axis on the left) was determined by 2-dimensional fluorescence-intensity distribution analysis/anisotropy without (dotted bars) or with autofluorescence correction (filled bars). As control, the count rate of the samples in 1 detection channel (y-axis on the right) is shown as well (line with triangles).
the real activation value can be restored ( Fig. 6B) , if autofluorescence correction is performed. Thus, this method is a valuable tool to identify false-positive compounds in screening campaigns and to validate identified hits with high fidelity.
CONCLUSION
The drug-mediated reactivation of mutant p53 is one important strategy in the treatment of cancer. This assertion is clearly supported by the fact that a wide range of mutant p53 proteins are susceptible to reactivation. The difference between latent and active p53 has not been defined completely at the molecular level; however, several activation models exist. In this study, we applied the strengths of the confocal fluorescence spectroscopy to detect activators of latent p53. To do that, a new protocol for both human wild-type latent and activated p53 was established. An assay system that enables the determination of binding affinities of human wild-type latent and activated p53 to fluorescently labeled DNA was built. Not only is the 2D-FIDA anisotropy detection a valuable technology in primary screening, but also it can be successfully applied as a highly sensitive tool to select and correct for false positives at the hit validation stage. This approach is of key importance for decreasing the attrition in early drug discovery. The validity of this approach, even for the true correction of autofluoresence, was underlined in a simulation study, which demonstrated that in the presence of autofluorescence, potent activators of latent p53 can be safely determined. 
